GlassScriptPhysician profile
Kevin Holthaus
NPI 1003893215
$8,454.20
in general payments reported to CMS, 2019-2025
58 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $781 · 2021: $1,211 · 2022: $1,538 · 2023: $1,282 · 2024: $1,251 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,204.73 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $1,093.35 | 2019-2025 | |
| Lilly USA, LLC | $780.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $629.58 | 2019-2025 | |
| Novo Nordisk INC | $553.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $495.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $266.34 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $252.64 | 2019-2025 | Veozah, Myrbetriq |
| Antares Pharma, INC. | $230.09 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $227.79 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.44 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $179.57 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.05 | 2019-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $152.52 | 2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $132.22 | 2019-2024 | Austedo Xr |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Holthaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.